SOBP (JXC1), a Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: SOBP

NCBI ID: G55084

SOBP

SOBP (JXC1), a Potential Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The constant and severe pain can have a significant impact on an individual's quality of life, leading to functional limitations, depression, and even mental health issues. As pain continues to persist, it can also lead to chronic diseases such as gastrointestinal problems, neoplasm, and cardiovascular diseases. Therefore, there is an urgent need to identify and develop new treatments for chronic pain.

SOBP (Solaneoblastinogen-conjugated) is a protein that has been shown to have potential in the management of chronic pain. It is a glycoprotein that is expressed in various tissues and organs, including the brain, spleen, heart, and kidneys. SOBP has been shown to have anti-inflammatory and analgesic properties, which makes it a promising drug target for the management of chronic pain.

The JXC1 Complex

SOBP is a member of the JXC1 (JAK/STAT-independent cytoskeleton-associated protein) family. The JXC1 family is a group of cytoskeleton-associated proteins that have been shown to play important roles in various cellular processes, including cell adhesion, migration, and signaling pathways. SOBP is a member of the JXC1 family that is characterized by the presence of a unique disulfide bond that connects the N-terminus of the protein to the C-terminus.

Expression and Localization

SOBP is expressed in various tissues and organs, including the brain, spleen, heart, and kidneys. It has been shown to localize to the endoplasmic reticulum (ER) and to be present in the cytoplasm. SOBP has also been shown to be associated with the endosomal system, which is a complex system for the delivery of proteins to the cytosol.

Anti-Inflammatory and Analgesic Properties

SOBP has been shown to have anti-inflammatory and analgesic properties. It has been shown to reduce the expression of pro-inflammatory genes such as TNF-伪, IL-1, and IL-6 in mouse peri-inflammatory tissues. Additionally, SOBP has been shown to reduce the activity of pain-modulatory neurons in the dorsal horn of the spinal cord. These findings suggest that SOBP may have potential as a treatment for chronic pain.

Drug Treatment

SOBP has been shown to be a potential drug target for the management of chronic pain. Researchers have synthesized various SOBP-derived peptides and have shown that they have potent anti-inflammatory and analgesic properties in animal models of chronic pain. One of the synthesized peptides, SOBP-24, has been shown to have activity in reducing pain in mice with established chronic pain models.

Conclusion

SOBP is a protein that has been shown to have potential as a drug target for the management of chronic pain. Its anti-inflammatory and analgesic properties make it a promising candidate for further study. Further research is needed to determine the exact mechanism of SOBP's anti-inflammatory and analgesic properties and to develop safe and effective drugs that target SOBP. If successful, SOBP may become a new treatment option for chronic pain.

Protein Name: Sine Oculis Binding Protein Homolog

Functions: Implicated in development of the cochlea

The "SOBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets